Medicine profile
Orforglipron
Once-daily oral, non-peptide GLP-1 receptor agonist. GLP-1 activity does not make it a peptide.
- Generic name
- Orforglipron
- Also known as
- Foundayo
- Sponsor and licensing
- Eli Lilly (originator)
- Mechanism
- GLP-1 receptor agonist
- Molecular type
- Small molecule (non-peptide) (mechanism and molecular type are recorded separately: GLP-1 activity does not make a medicine a peptide)
Brands, routes and formulations
Foundayo
oral 路 once-daily tablet
- United States: Chronic weight management (1 Apr 2026)
Regulatory status by jurisdiction
Authorisation, launch and funded access are three different things and are shown separately. "Not recorded" means GLPInfo has not verified an event, not that nothing has happened.
| United States (FDA) | United Kingdom (MHRA) | European Union (EMA / EC) | |
|---|---|---|---|
| Regulatory authorisation | 1 Apr 2026 路 FoundayoChronic weight management | Not recorded | Not recorded |
| Commercial launch | Not recorded | Not recorded | Not recorded |
| Funded access | Not recorded | Not recorded | Not recorded |
Development timeline
Orforglipron
Dashed line: today, 14 Sep 2026. Future windows are conditional. Approval, launch and funded access are separate milestones.
Select a marker to open its record in the pipeline view, which has the detail panel and the accessible list.
Next milestone and forecast rationale
No forecast is published for Orforglipron. Approved medicines only carry forecasts for new indications or jurisdictions when a filing anchor exists.
Trial evidence
| Trial | Phase | Population | Duration | Results |
|---|---|---|---|---|
| ATTAIN-1Eli Lilly 路 oral, once daily | 3 | 3,127 adults without type 2 diabetes | 72 weeks | On file from the research workbook; withheld until the primary publication or registry record is attached. |
GLPInfo does not rank unrelated trials against each other or quote "weight loss per week": populations, durations and methods differ and weight change is not linear. Results appear here per trial and dose arm, with comparator, endpoint and source, once cited.
Known limitations and official labels
This profile is assembled from the regulatory records and sponsor statements GLPInfo has verified; it is not a complete review of Orforglipron. The current official label in each jurisdiction is the authority on indications, populations and safety.
Review date and correction history
Records last checked 13 Sep 2026. No corrections have been made to the records on this profile; every record is at version 1. Report a correction.
Related news
FDA approves Foundayo (orforglipron), the first oral small-molecule GLP-1 medicine for weight management
On 1 April 2026 the FDA approved Foundayo, Eli Lilly's once-daily oral orforglipron, for adults with obesity or with overweight and a weight-related condition. UK and EU status are separate records and are verified independently.
Follow Orforglipron All medicines Compare UK Foundayo prices